Scientific presentations

Talks about the application of metabolomics

biocrates makes quantitative metabolomics accessible to scientists globally. Our customers and partners speak about the future of research and health in many different settings. Here we share some of their insights in different disease areas such as pharmacology, oncology, cardiovascular diseases, neurology, infectious diseases, or epidemiology.

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second most deadly cancer by 2040, owing to the high incidence of metastatic disease and limited responses to treatment. Less than half of all patients respond to the primary treatment for PDAC, chemotherapy, and genetic alterations alone cannot explain this. Using shotgun metagenomic sequencing and metabolomic screening, we show that the microbiota-derived tryptophan metabolite indole-3-acetic acid (3-IAA) is enriched in patients who respond to treatment.

read more
Advancing cancer treatment by targeting dysregulated metabolism – A roadmap

Advancing cancer treatment by targeting dysregulated metabolism – A roadmap

Cancer cells adjust metabolic program to their specific energy needs in response to challenging microenvironment, which frequently results in cancer cell “addiction” to certain metabolic pathways. Those “addictions” could be deployed as treatment targets. Metabolic profiling by providing quantitative measure of metabolic processes offers attractive strategy for investigation of not only cancer cells “addictions” but also metabolic switches contributing to treatment resistance.

read more

Upcoming events